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Decreases in high-density lipoprotein cholesterol (HDL-C) levels are associated with an
increased risk of coronary artery disease (CAD), whereas increased HDL-C levels are related
to  a decreased risk of CAD and myocardial infarction. Although HDL prevents the oxida-
tion of low-density lipoprotein under normal conditions, it triggers a structural change,
inhibiting antiarteriosclerotic and anti-inﬂammatory functions, under pathological condi-
tions such as oxidative stress, inﬂammation, and diabetes. HDL can transform into various
structures based on the quantitative reduction and deformation of apolipoprotein A1 and is
the  primary cause of increased levels of dysfunctional HDL, which can lead to an increased
risk  of CAD. Therefore, analyzing the structure and components of HDL rather than HDL-Cexercise training
high-density lipoprotein cholesterol
(HDL-C)
after the application of an exercise training program may be useful for understanding the
effects of HDL.
© 2016 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access
article under the CC BY-NC-ND license
causes structural alterations under pathological conditions1.  Introduction
When blood cholesterol increases by 1%, the frequency of
ischemic heart disease or coronary heart disease (CHD)
increases by 2%.1 High-density lipoprotein (HDL), which is
small in size and rich in proteins, is one of the lipoproteins
which bind to high-density cholesterols, known as a media-
tor for preventing the risk of CHD. HDL is commonly regarded
as an index of health status because it reduces blood clot-
ting by stimulating the secretion of nitric oxide (NO) inside
endothelial cells and prevents inﬂammation by inhibiting the
expression of inﬂammatory factors of endothelial cells. Addi-
tionally, HDL prevents the oxidation of low-density lipoprotein
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(LDL) to limit the interaction and adsorption of monocytes and
endothelial cells, while releasing cholesterol from endothe-
lial cells via the reverse transport of cholesterol. Moreover,
LDL prevents the secretion of endothelin, which is a powerful
vasoconstrictor.2
HDL was recently reported to exert antiatherogenic effects
through numerous biological mechanisms and has anti-
inﬂammatory, antiapoptotic, and antithrombotic effects in
the endothelial cells of healthy individuals.3–7 Although HDL
prevents the oxidation of LDL under normal conditions, it Physical Education, Keimyung University, 1095 Dalgubeuldaero,
such as oxidative stress, inﬂammation, and diabetes, which
may reduce the antiarteriosclerotic and anti-inﬂammatory
functions. Decreases in HDL-cholesterol (HDL-C) levels have
vier. This is an open access article under the CC BY-NC-ND license
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een shown to increase the risk of coronary artery disease
CAD),8,9 whereas increased HDL-C reduces the risk of both
AD and myocardial infarction. However, in recent clinical
tudies of lipid-modifying drugs, the inﬂuence was shown
o be minimal. Therefore, a new approach for examining the
tructure and components of HDL, rather than using an HDL-
-based approach, is required. Particularly, because HDL can
ransform into various forms via changes in its structure and
omponents, its antiarteriosclerotic and anti-inﬂammatory
ffects can also decrease. Therefore, studies should focus on
he structure and components of HDL rather than HDL-C for
he prevention and treatment of cardiovascular diseases.
.1.  Function  of  HDL-C:  reverse  cholesterol  transport
DL-C plays an important role in the homeostasis of total
holesterol. This can be achieved through a mechanism
nown as reverse cholesterol transport (RCT), by which HDL-C
an prevent the occurrence of arteriosclerosis.10 RCT removes
urplus cholesterol from macrophages on the artery walls and
ischarges it out of the body after transport to the liver, thereby
uppressing atherosclerotic carotid stenosis.11 As RCT is the
nly mechanism removing surplus cholesterol inside the body,
he maintenance of an appropriate HDL-C-concentration as
ell as its function are essential for preventing cardiovascu-
ocerebral diseases.
The basic unit of HDL particles is apolipoprotein A1 (ApoA-
), which is a lipoprotein containing nearly no lipid. ApoA-1 is
ynthesized in the liver and gastrointestinal tract and secreted
nto the plasma. Through the action of ATP-binding cas-
ettes transporter A1, which is a membrane protein present
n peripheral tissue, intracellular cholesterol is transported
o ApoA-1 to form HDL.12 Free cholesterol on the surface of
DL is then esteriﬁed by lecithin cholesterol acyltransferase
LCAT),13 and the cholesterol ester moves towards the heart
o form HDL3, which eventually forms small spheres. HDL3
hen binds to large amounts of cholesterol via the action
f LCAT and various other serum factors, which combine to
orm larger HDL2. HDL2, which binds cholesterol ester (CE),
eacts with ApoB lipoproteins (very low-density lipoprotein,
ntermediate-density lipoprotein, LDL, chylomicrons, etc.) and
ransfers cholesterol ester via the action of cholesteryl ester
ransfer protein, obtaining neutral lipids in exchange. HDL2,
hich contains large amounts of neutral lipids, is then recon-
erted into HDL3 after the removal of cholesterol through the
ction of scavenger receptor class B type I or is disintegrated
y hepatic lipase.14
.2.  Dysfunctional  HDL-C  and  cardiovascular  disease
DL prevents the oxidization of LDL under normal condi-
ions. However, in some pathological conditions including
xidative stress, inﬂammation, and diabetes, HDL undergoes
 structural change and loses its antiarteriosclerotic and anti-
nﬂammatory functions, eventually becoming dysfunctional
DL.15 In various diseases, the levels of dysfunctional HDL
xcessively increases. HDL can be classiﬁed into various sub-
ypes depending on the lipids and proteins binding to the HDL,
hereas ApoA-1 is the most important protein component of
DL. ApoA-1 performs its function with HDL by interacting213
with various proteins. Thus, the decrease and deformation
of ApoA-1 are major causes for HDL dysfunction. Deforma-
tion of ApoA-1 decreases the binding strength to lipids, which
decreases HDL stability. The HDL level in a CAD patient and
sacchariﬁcation of ApoA-1 was examined to determine their
association with diabetes.16 The sacchariﬁcation of ApoA-1
was conﬁrmed based on the formation of multimers.17
When HDL levels are decreased or when HDL function
is altered, many  changes indicating damage to the kidney
are observed in the blood vessels. As the kidney function
decreases, the HDL function or level decreases. Therefore,
among patients with chronic kidney diseases, those with
highly disrupted HDL distributions are prone to developing
cardiac diseases. However, although RCT still occurs on the
surfaces of tissues cells, additional studies are needed to
determine the inﬂuence of increased HDL cholesterol level and
HDL function on CAD (Figs. 1 and 2).
The quantitative decrease and sacchariﬁcation of ApoA-
1 are related to aging. Comparison of HDL  between elderly
and young participants showed that the composition of pro-
tein and lipid is signiﬁcantly altered, particularly in terms
of protein contents directly related to acute syndromes such
as serum amyloid A (SAA). Therefore, dysfunctional HDL
may increase along with various aging-related phenomena.
Recent studies showed that chronic inﬂammation alters HDL
structure. This dysfunctional HDL in turn increases SAA and
decreases ApoA-1 concentration. By separating the subtype
HDL3, which is small in size and high in density, ApoA-1
and SAA can be quantitatively analyzed to determine the
ﬂuctuations in dysfunctional HDL.18,19 SAA and decreased
anti-inﬂammatory function of HDL was found in the HDL
of a chronic kidney disease patient. The HDL extracted
from patients with acute coronary syndrome, psoriasis, and
rheumatoid arthritis showed increased SAA.
1.3.  Dysfunctional  HDL-C  and  obesity
Obesity, along with decreased concentrations of HDL-C, also
causes HDL-C dysfunction. Recent studies have demonstrated
that HDL-C may accelerate atherosclerotic carotid stenosis,
which differs from the results of previous studies.20 Addition-
ally, unlike HDL-C, which performs a normal function, the
HDL-C extracted from the blood plasma of a patient with acute
inﬂammation did not suppress monocyte chemotaxis.21 Some
reports have shown that the antioxidation effect of HDL-C
does not properly occur in obese patients. For instance, Sor-
rentino et al22 found that HDL-C separated from the blood
plasma of type 2 diabetes patients showed signiﬁcantly low
endothelial protective activity.
In addition, decreased cellular cholesterol efﬂux capacity
was predicted as another major factor inducing cardiovascu-
locerebral diseases in obese patients. The cellular cholesterol
efﬂux capacity was signiﬁcantly low in adults with CAD
compared with healthy adults.23 The mechanism of obesity
involving HDL-C showed highly increased free fatty acid and
very LDL. This in turn induces excessive activation of RCT,
further accelerating HDL-C catabolism.24 Moreover, in obese
patients, activation of the cholesterol ester transfer protein
LCAT, liver lipid proteinase, and protein phospholipid trans-
fer protein is also altered.25 A previous study suggested that
214  Integr Med Res ( 2 0 1 6 ) 212–215
Fig. 1 – Role of HDL-C and reverse cholesterol transport.
ABCA-1, ATP-binding cassette transporter A-1; ABCG1, ATP-binding cassette subfamily G member 1; ApoA-1,
apolipoprotein A-1; CETP, cholesteryl ester transfer protein; HDL, high density lipoprotein; LCAT, lecithin cholesterol
acyltransferase; LDL-R, low density lioprotein receptor; SR-B1, scavenger receptor class B type 1.
Fig. 2 – The properties of functional HDL and dysfunctional HDL.
ApoA-1, apolipoprotein A-1; ApoCIII, apolipoprotein CIII; ApoE, apolipoprotein E; LP-PLA2, lipoprotein-associated
; SAAphospholipase A2; Pon1, serum paraoxonase/arylesterase 1
obesity not only promotes the removal of ApoA-1, but also sup-
presses its expressed sequence at the cellular level,26 although
this mechanism remains to be conﬁrmed.
1.4.  Effect  of  exercise  training  in  HDL-C
HDL in athletes differed from that in ordinary individuals,
showing a larger size and higher density. Thus, the quality
of HDL is related to health. However, although HDL struc-
ture and function are related to cardiovascular diseases, few
studies have examined postexercise training.27 According to
the Aerobic Center Longitudinal Study, death rates due to
cardiovascular disease and differences in ﬁtness level are
unrelated.28 However, strength ﬁtness was found to be related
to the risk of metabolic syndrome in males.29 Roberts et al30
showed increased HDL redox activity in an overweight training
group compared with a nontraining group. Dysfunctional HDL
was found to be low in the overweight training group, indicat-
ing that the risk of CHD from obesity stems from differences
in strength ﬁtness.
Overweight or obese people typically show high levels of
oxidized LDL,31 whereas those with high muscular strength
show decreased levels of oxidized LDL.32 Da Silva et al331, serum amyloid A1.
reported that resistance exercises enhance LDL-C clearance,
whereas Volkmann et al34 reported that dysfunctional HDL
decreased after low-intensity exercise of patients with sys-
temic lupus erythematosus. Therefore, metabolic syndrome
and cardiovascular disease are highly attributed to dysfunc-
tional HDL. The application of exercise programs is thought
to be effective for reducing the risk of CHD by reinforcing the
anti-inﬂammatory function of HDL.
2.  Conclusion
Under normal conditions, HDL prevents the oxidization of
LDL, whereas HDL undergoes structural alterations under
pathological conditions such as oxidative stress, inﬂamma-
tion, and diabetes, which reduces the antiarteriosclerotic and
anti-inﬂammatory functions. HDL can be transformed into
various forms depending on the structure and components,
and such dysfunctional HDL-C is closely related to CAD risk.
The quantitative decrease or deformation of ApoA-1 is a
major factor increasing dysfunctional HDL, demonstrating
its antiarteriosclerotic and anti-inﬂammatory effects. There-
fore, in order to utilize HDL to determine health information,
analysis of the structure and components of HDL after the
Na
t
C
T
r. Ahn and K. Kim/HDL-C and exercise training 
pplication of an exercise program should be combined with
he analysis of HDL-C.
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